Journal article icon

Journal article

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.

Abstract:

WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: A growing body of evidence supports the anti-cancer effect of histone deacetylase inhibitors (HDACi) in vitro, via multiple pathways, and many Phase I clinical trials have shown them to be well-tolerated in a range of malignancies. Combined therapies, including with radiation, present an exciting area of current and planned study. This review summarises the evidence to date, including pre-clinical data and clinical trials, of the anti...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Sharma, NL More by this author
Groselj, B More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Journal:
BJU international
Volume:
111
Issue:
4
Pages:
537-542
Publication date:
2013-04-05
DOI:
EISSN:
1464-410X
ISSN:
1464-4096
URN:
uuid:ce45922d-3bf8-4fb2-ab9a-7962f2cfb3cf
Source identifiers:
394963
Local pid:
pubs:394963

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP